HR-Positive Breast Cancer: Patient Perspectives on ctDNA-Guided Treatment Decisions

This segment explores patient perspectives and acceptance of biomarker-driven treatment strategies in hormone receptor–positive, HER2-negative metastatic breast cancer. Dr. Adam Brufsky raises the question of how patients may respond to treatment changes based on emerging molecular findings, particularly in the context of potential approval of ctDNA-guided interventions.

Dr. Hope S. Rugo discusses how patients are increasingly drawn to personalized treatment approaches, particularly when biomarker results suggest a more targeted strategy. She notes that while this approach may be appealing, clinical decision-making must remain nuanced, especially for patients with stable or low-burden disease where immediate treatment changes may not always be necessary.

Dr. Mabel Mardones adds that patients are actively asking about ctDNA monitoring and molecular testing, reflecting growing awareness and engagement. Overall, this segment highlights the importance of balancing patient expectations with clinical judgment in the evolving landscape of precision oncology.